Quest Diagnostics to develop multi-cancer blood test with MD Anderson Center

Quest Diagnostics (DGX) announced a collaboration with The University of Texas MD Anderson Cancer Center to improve the assessment of elevated risk of cancer in individuals who would benefit from medically appropriate cancer screenings. Quest will develop and validate a laboratory-developed blood test based on circulating protein biomarkers associated with high risk for one or more cancers, including colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal and stomach. Quest will base the test on a developmental license to technology and intellectual property associated with the Multi-Cancer Stratification Test – MCaST -, a cohesive risk model developed at MD Anderson. Quest plans to refine and further develop and validate the MCaST technology for its own lab-developed test. Assuming successful test validation, the parties may agree for Quest to exercise rights to commercialize the test, with the goal to make it available to providers in North America in 2026.